Prospective, nonblind trial of methotrexate on seronegative spondyloarthropathy

This study was designed to see the efficacy of methotrexate (MTX) in patients with seronegative spondyloarthropathies viz ankylosing spondylitis (AS), juvenile chronic arthritis (JCA) and Reiter's syndrome (ReS) / Reactive arthritis (RA). Thirty two patients were randomly selected and methotrexate was given orally to each patient. 6 (18.7%) and 11 (34.3%) cases showed complete and partial improvement respectively. Individual therapeutic response with MTX were 38.9% in ankylosing spondylitis, 70.0% in JCA and 75% in RS/ReA respectively. The improvement was significant (P<.001).